Trends in Pharmacological Sciences
Volume 17, Issue 10, October 1996, Pages 364-372
Pharmacology of adenosine A2A receptors
References (42)
- et al.
Brain Res.
(1990) - et al.
J. Biol. Chem.
(1990) - et al.
Eur. J. Pharmacol.
(1995) - et al.
Eur. J. Pharmacol. Mol. Pharmacol. Sect.
(1992) Eur. J. Pharmacol.
(1994)Eur. J. Med. Chem.
(1996)Bioorg. Med. Chem. Lett.
(1994)- et al.
J. Biol. Chem.
(1995) - et al.
Biochem. Pharmacol.
(1994) Pharmacol. Rev.
(1994)
Annu. Rev. Pharmacol. Toxicol.
(1995)
J. Med. Chem.
(1992)
Trends Pharmacol. Sci.
(1993)
Curr. Med. Chem.
(1995)
J. Neurochem.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
(1980)
Mol. Pharmacol.
(1986)
Biochemistry
(1979)
Mol. Pharmacol.
(1991)
Cited by (308)
The adenosine A (2A) receptor antagonist SCH58261 protects photoreceptors by inhibiting microglial activation and the inflammatory response
2022, International ImmunopharmacologyCitation Excerpt :It was hypothesized that early regulation of adenosine receptors could delay or prevent photoreceptor degradation, and 1,2 days after injury was considered as the time point for early adenosine receptor intervention [15]. SCH58261 is a potent and selective competitive A2AR antagonist with a stable chemical structure [16]. SCH58261 has high affinity for human A2AR and is the most potent antagonist binding to human A2AR among several common A2AR antagonists, while SCH58261 has good bioavailability [17].
Copyright © 1996 Published by Elsevier Ltd.